Supriya Lifescience profit declines 42% amid higher costs

Supriya Lifescience Limited reported a 42% year-on-year decline in profit for the quarter ended September 30, 2026, to Rs 29.250 crore, as total expenses rose 27% to Rs 170.811 crore while revenue from operations increased 3% to Rs 206.297 crore. Higher material consumption, other expenditure and depreciation outweighed the increase in income.

Why did Supriya Lifescience’s September-quarter profit decline?

Supriya Lifescience’s September-quarter profit declined because its expenses grew faster than income. Total expenses reached Rs 170.811 crore in the quarter ended September 30, 2026, versus Rs 134.240 crore a year earlier, while total income rose to Rs 208.589 crore from Rs 202.558 crore.

Material consumption was Rs 92.455 crore, up from Rs 60.683 crore in the September 2025 quarter, an increase of 52%. Other expenditure rose 36% to Rs 63.692 crore from Rs 46.975 crore, and depreciation and amortisation increased 42% to Rs 9.459 crore from Rs 6.639 crore.

The expense increase reduced profit before tax to Rs 37.778 crore from Rs 68.318 crore, a 45% decline. Tax expense fell to Rs 8.528 crore from Rs 17.891 crore, but the lower tax charge did not offset the reduction in pre-tax profit, leaving profit for the period at Rs 29.250 crore versus Rs 50.427 crore.

How did Supriya Lifescience’s revenue compare with its profit?

Supriya Lifescience added Rs 6.464 crore of operating revenue year on year, but profit for the period fell by Rs 21.177 crore. Revenue from operations was Rs 206.297 crore in the September 2026 quarter, compared with Rs 199.833 crore in the quarter ended September 30, 2025.

Other income declined to Rs 2.292 crore from Rs 2.725 crore, so total income increased by Rs 6.031 crore to Rs 208.589 crore. That increase was smaller than the Rs 36.571 crore rise in total expenses, which included higher material consumption and other expenditure.

The sequential comparison was different for net profit. Revenue from operations increased from Rs 189.747 crore in the quarter ended June 30, 2026, while profit for the period increased from Rs 24.043 crore; however, profit before tax declined from Rs 40.792 crore as total expenses rose from Rs 151.603 crore.

Basic and diluted earnings per share were Rs 3.63 for the September 2026 quarter, compared with Rs 6.27 a year earlier and Rs 2.99 in the immediately preceding quarter. The company’s paid-up equity share capital was unchanged at Rs 16.097 crore across the three reported quarterly periods.

What do Supriya Lifescience’s half-year results show?

Supriya Lifescience’s operating revenue rose 15% in the half year ended September 30, 2026, while profit for the period fell 37%. Half-year revenue from operations was Rs 396.044 crore, compared with Rs 344.907 crore in the corresponding six months of 2025, and profit was Rs 53.293 crore versus Rs 85.217 crore.

Total expenses increased 37% to Rs 322.414 crore from Rs 234.576 crore during the six-month comparison. Material consumption was Rs 201.855 crore, nearly double the Rs 104.459 crore reported a year earlier, while other expenditure increased to Rs 121.106 crore from Rs 85.888 crore.

Profit before tax decreased 32% to Rs 78.570 crore from Rs 115.730 crore. Employee benefit expense rose to Rs 54.633 crore from Rs 47.169 crore, while depreciation and amortisation rose to Rs 18.399 crore from Rs 13.090 crore.

What changed in Supriya Lifescience’s working capital and cash balances?

Supriya Lifescience’s inventories increased to Rs 265.168 crore at September 30, 2026, from Rs 159.597 crore at March 31, 2026, while trade receivables declined to Rs 125.580 crore from Rs 219.448 crore. The cash-flow statement recorded a Rs 105.571 crore outflow from inventory during the half year.

Net cash generated from operating activities was Rs 60.884 crore for the six months ended September 30, 2026. Operating profit before working-capital changes was Rs 91.492 crore, with the inventory outflow partly offset by a Rs 93.869 crore reduction in trade receivables.

Cash and cash equivalents increased to Rs 41.021 crore at September 30, 2026, from Rs 27.480 crore at March 31, 2026. Bank balances other than cash and cash equivalents rose to Rs 34.910 crore from Rs 10.065 crore, while the balance sheet reported no current or non-current borrowings at either date.

Investing activities used Rs 38.832 crore in the half year, including Rs 35.434 crore spent on fixed assets and Rs 8.116 crore on investments. Total equity increased to Rs 1,242.600 crore at September 30, 2026, from Rs 1,197.733 crore at March 31, 2026.

What did Supriya Lifescience disclose about exports and management?

Supriya Lifescience said material intended for export in the first quarter of financial year 2026-27 was detained by Customs while in transit. The company said Customs cleared and released the material, which was successfully exported on October 2, 2026, but it did not disclose the material’s value or its revenue effect.

Supriya Lifescience’s audit committee reviewed, and its board approved, the standalone unaudited September-quarter and half-year results on November 6, 2026. The independent reviewer stated on the same date that nothing had come to its attention to suggest the financial statement contained a material misstatement under the applicable reporting requirements.

The board also approved Mangesh Vaze’s appointment as chief operating officer and senior management personnel on November 6, 2026, effective that day. Supriya Lifescience said Vaze has approximately 34 years of experience in production, process engineering, active pharmaceutical ingredient manufacturing and operations.

Conclusion

Supriya Lifescience recorded 3% September-quarter operating-revenue growth, but a 27% increase in expenses reduced profit for the period by 42% to Rs 29.250 crore. The half-year pattern was similar: revenue rose 15% to Rs 396.044 crore while profit declined 37% to Rs 53.293 crore, led by higher material consumption and other expenditure.

The next reported period will show whether the material exported on October 2, 2026 after Customs clearance contributed to later revenue, although Supriya Lifescience did not quantify its potential effect. The November 6, 2026 appointment of a chief operating officer is another disclosed operational development, but the filing gives no cost-reduction target or profitability guidance.